Literature DB >> 24715742

Risperidone: stuttering.

Joyce A Generali1, Dennis J Cada2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2014        PMID: 24715742      PMCID: PMC3971108          DOI: 10.1310/hpj4903-242

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  9 in total

1.  Alprazolam, citalopram, and clomipramine for stuttering.

Authors:  J P Brady; Z Ali
Journal:  J Clin Psychopharmacol       Date:  2000-04       Impact factor: 3.153

2.  A case of risperidone-induced stuttering.

Authors:  H J Lee; H S Lee; L Kim; M S Lee; K Y Suh; D I Kwak
Journal:  J Clin Psychopharmacol       Date:  2001-02       Impact factor: 3.153

3.  Risperidone reduces tic-like motor behaviors and linguistic dysfluencies in severe persistent developmental stuttering.

Authors:  Alessandro Tavano; Pierpaolo Busan; Massimo Borelli; Giovanna Pelamatti
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

Review 4.  Developmental and persistent developmental stuttering: an overview for primary care physicians.

Authors:  John V Ashurst; Megan N Wasson
Journal:  J Am Osteopath Assoc       Date:  2011-10

5.  Stuttering: neuropsychiatric features measured by content analysis of speech and the effect of risperidone on stuttering severity.

Authors:  G A Maguire; L A Gottschalk; G D Riley; D L Franklin; R J Bechtel; J Ashurst
Journal:  Compr Psychiatry       Date:  1999 Jul-Aug       Impact factor: 3.735

6.  Risperidone for the treatment of stuttering.

Authors:  G A Maguire; G D Riley; D L Franklin; L A Gottschalk
Journal:  J Clin Psychopharmacol       Date:  2000-08       Impact factor: 3.153

7.  Risperidone induced stuttering.

Authors:  Devender Singh Yadav
Journal:  Gen Hosp Psychiatry       Date:  2010-02-20       Impact factor: 3.238

Review 8.  Pharmacological agents for developmental stuttering in children and adolescents: a systematic review.

Authors:  Alexander Boyd; Katharina Dworzynski; Peter Howell
Journal:  J Clin Psychopharmacol       Date:  2011-12       Impact factor: 3.153

9.  Persistent developmental stuttering: treatment with risperidone.

Authors:  Sanjeev Ranjan; Vinit Sawhney; Prabha S Chandra
Journal:  Aust N Z J Psychiatry       Date:  2006-02       Impact factor: 5.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.